| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-11-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-12-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-20-2025 | 12-31-2024 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exc...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosisTopline data expected in mid-2026WAL...
Freedom Capital Markets analyst Ilya Zubkov initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and an...
Jones Trading analyst Debanjana Chatterjee initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Buy rating and ann...
Raymond James analyst Chris Raymond initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Strong Buy rating and ann...
RBC Capital analyst Brian Abrahams initiates coverage on Sionna Therapeutics (NASDAQ:SION) with a Sector Perform rating and ...
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $...
